Acalabrutinib shows improved cardiovascular safety over ibrutinib, reducing atrial fibrillation and hypertension risks in CLL patients. Real-world data confirm ELEVATE-RR trial results, highlighting ...
This year’s most-read articles on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) explored treatment adherence patterns, patient symptom assessment, research on treatment ...
Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...
Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...
Over an 18-month follow-up, 102 (52.8%) VEN-O patients discontinued after completing the fixed-duration period; 597 (37.9%) BTKi and 57 (29.5%) VEN-O patients discontinued treatment prematurely. The ...
-New insights show Black, Hispanic, and Asian patients have more negative emotional experiences and outlooks with their chronic lymphocytic leukemia (CLL) diagnosis and treatment journeys-CLL is one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results